Secondary objective was to investigate the treatment effect on ne

Secondary objective was to investigate the treatment effect on neurological status and quality of life. Criteria for considering studies for this review Types of studies All randomised and quasi-randomised controlled trials were eligible for inclusion. Types of participants Adult patients were

eligible if they had TC or MRI-demonstrated brain metastases from histologically proven solid tumors, required WBRT, with any Karnofsky performance status and RPA class with brain metastases originated from solid tumors, excluding small-cell lung cancer, germ cell tumors, and lymphomas. There were no restrictions regarding gender or nationality. Trials of prophylactic whole brain radiotherapy CHIR-99021 manufacturer in which whole brain radiotherapy was used with no evidence of existing brain metastases were excluded. Studies that examined

OSI-027 purchase the use of surgery or whole brain radiotherapy, or both, for single brain metastases were also excluded Types of intervention All trials were included where adult patients were randomly assigned to receive WBRT given in daily fractions, with or without radiosensitizer. Types of outcome measures Data for the following outcome measures were analyzed: The overall survival in six months. Intracranial progression-free duration was defined as the time from randomization or entry to the trial until progressive brain disease is diagnosed. Local brain response was considered as the percentage of patients achieved complete response (CR) or partial response (PR) to treatment. Complete response was defined as complete Torin 2 solubility dmso radiographic disappearance of brain metastases. Partial response was defined as more

than 50% decrease in size of the brain metastases on CT or MR imaging. Local brain control was reported to as the percentage of patients with unchanged or improved serial post-treatment CT or MRI scans judged either as a complete response (CR), partial response (PR), or stable Digestive enzyme disease (SD), with improving or stable neurological symptoms or neurological examination results. SD is defined as a 0 to 50% decrease in size of all lesions with stabilization neurological symptoms or neurological examination results and stable dexamethasone dose. Progressive disease is defined as an increase in the size of any lesion, the development of new lesions, or a decrease in neurological symptoms or examination requiring an increase in dexamethasone dose. Quality of life, symptom control and neurological function assessed by any scale. Research strategy for identification of studies Medline and manual research was done (completed independently and in duplicate) to identify all published (manuscripts and abstracts) randomized controlled trials (RCTs) that comparing WBRT plus radiosensitizer treatment for brain metastases to WBRT alone.

Comments are closed.